Benzonase® endonuclease portfolio

Choose API processing to improve API properties right from the start and avoid the risk of dealing with a poorly water-soluble API in formulation development or the need to start API development from scratch.

 

Whichever API processing method you decide to use, we pr...

Deviron® C16 detergent provides robust inactivation of enveloped viruses. In addition, it may be used to achieve cell lysis for viral gene therapy vector production processes. It does not require a REACH authorization and is a suitable alternative to Triton™ X-100  detergent.

Meglumine is a versatile product applied either as a counterion to form a salt with the API or as a functional excipient. Traditionally applied as a counterion in contrast media, meglumine is an organic base which can also be used as a functional excipient to enhance API solubility, improve API stabili...

Poor solubility of APIs is a critical challenge in the drug development process. Our Parteck® MXP range of polymers includes two polyvinyl alcohol-based excipients, specifically designed and optimized for hot melt extrusion to increase solubility for a broad range of APIs.

With a lower de...

Poor solubility of APIs is a critical challenge in the drug development process. Our Parteck® MXP range of polymers includes two polyvinyl alcohol-based excipients, specifically designed and optimized for hot melt extrusion to increase solubility for a broad range of APIs.

 
q...

Parteck® PLX 188 is a dissolution rate enhancing excipient that also acts as a robust water-soluble, hydrophilic lubricant. With its optimized particle size, Parteck® PLX 188 poloxamer is designed with the needs of modern manufacturing in mind - such as direct compression and continuous manufacturing -...

Parteck® SLC mesoporous silica is a multi-functional excipient for both solubility enhancement and particle engineering.

When used as a solubility enhancing excipient, the high surface area and small pores of Parteck® SLC mesoporous silica enable optimal stabilization of the more solubl...

Specifically developed for high-risk applications, our portfolio of high-quality sugars, polyols, amino acids, and surfactants simplifies selection when you face critical challenges such as preventing aggregation during manufacturing.

The Viscosity Reduction Platform of proprietary excipient combinations enables subcutaneous formulation of highly concentrated protein biologics, bringing together increased concentrations and improved downstream processing.

The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). 

Enhance dissolution rate and lubrication with a single high performance excipient.

Parteck® PLX provides consistent performance, improved dissolution rate and reliable lubrication – all at the same time.

Several big pharma companies have added their names to a letter challenging suppliers in the healthcare industry to pledge to sustainability targets. 

Absorption of molecules from the gastrointestinal tract is an essential consideration when developing orally delivered medications. Solubility, the concentration of drug in solution, is essential for this to occur and it is important to also consider the dissolution rate of the molecule. For DCS Class IIa molecules, defined as having a slow dissolution rate, simple yet effective formulations can be developed. Parteck® PLX 188 excipient should be considered for these challenging molecules to increase dissolution rate, provide hydrophilic lubrication, and enable simple and costeffective manufacturing processes.

Merck tests new formulation of effective immunotherapy Keytruda to gain approval in time to extend the patent on the drug before it runs out in 2028. 

Absorption of molecules from the gastrointestinal tract is an essential consideration when developing orally delivered medications. Solubility, the concentration of drug in solution, is essential for this to occur and it is important to also consider the dissolution rate of the molecule. For DCS Class IIa molecules, defined as having a slow dissolution rate, simple yet effective formulations can be developed. Parteck® PLX 188 excipient should be considered for these challenging molecules to increase dissolution rate, provide hydrophilic lubrication, and enable simple and costeffective manufacturing processes.

Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution

Development of new active pharmaceutical ingredients (APIs) is lengthy and cost-intensive, thus avoiding any potential risk that may limit the product’s success is of utmost importance. Today, many APIs are not being commercialized as they are poorly water soluble and, as a result, exhibit too low bioavailability.PLX, MXP, SLC, Meglumine